Compare Bumble Inc (BMBL) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bumble Inc vs Bristol-Myers Squibb Co — how do they compare? Bumble Inc trades at $3 (market cap $382.16M), while Bristol-Myers Squibb Co trades at $58.49 (market cap $116.30B). The key difference: Bristol-Myers Squibb Co is far larger — about 304.3× Bumble Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.
| BMBL | BMY | |
|---|---|---|
Market Cap | $382.16M | $116.30B |
Sector | Technology | Health |
52-Week High | $8.57 | $62.37 |
52-Week Low | $2.70 | $42.60 |
Enterprise Value | $733.84M | $152.24B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMBL trades at $3.11, up 2.64% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported a Q1 2026 EPS beat but faces declining revenue and a net loss of -$693.14M for 2025. Recent news highlights a potential sale exploration and an AI-driven product overhaul to counter slowing growth and payer declines.
Outlook remains speculative with a consensus price target of $4.37, offering 40% upside, but risks include persistent losses, high debt, and intense competition. Execution of the strategic reset is critical for a turnaround, with cash flow improvements providing a slight cushion amid operational challenges.
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
